Antimutagenicity of benzo[a]phenothiazines in chemically induced mutagenesis

Masaru Tanaka, Kornélia Wayda, Joseph Molnár, Cyril Párkányi, Jean Jacques Aaron, Noboru Motohashi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The antimutagenicity of seven benzo[a]phenothiazines was screened against Salmonella typhimurium strain TA98 treated with 4-nitro-o-phenylenediamine which is a specific mutagen to the strain, and the results were compared to the antimutagenic activity of chlorpromazine (8), one of the 2-chlorophenothiazine derivatives - which have been shown to be the most effective mutagen inhibitors. Benzo[a]phenothiazines with methyl, oxo or hydroxyl substituent(s) at position 5, 6, 9 or 10 were used in the screening tests. 6-Hydroxy-5-oxo-5H-benzo[a]phenothiazine (6) reduced the induced mutation by 27%, being a more potent antimutagenic agent than chlorpromazine (8). The study of antimutagenicity is of great interest for the development of cancer chemopreventive agents which stop cancer progression in multistage carcinogenesis in which successive mutation sequences are required for a progression into full-fledged metastatic cancer.

Original languageEnglish
Pages (from-to)839-842
Number of pages4
JournalAnticancer research
Volume17
Issue number2 A
Publication statusPublished - Jan 1 1997

    Fingerprint

Keywords

  • 4-Nitro-o-phenylenediamine
  • Ames test
  • Antimutagenicity
  • Benzo[a]phenothiazines

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Tanaka, M., Wayda, K., Molnár, J., Párkányi, C., Aaron, J. J., & Motohashi, N. (1997). Antimutagenicity of benzo[a]phenothiazines in chemically induced mutagenesis. Anticancer research, 17(2 A), 839-842.